Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Conmed (CNMD) EPS (Weighted Average and Diluted) (2016 - 2025)

Conmed's EPS (Weighted Average and Diluted) history spans 16 years, with the latest figure at $0.54 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 50.0% year-over-year to $0.54; the TTM value through Dec 2025 reached $1.51, down 64.39%, while the annual FY2025 figure was $1.51, 64.47% down from the prior year.
  • EPS (Weighted Average and Diluted) reached $0.54 in Q4 2025 per CNMD's latest filing, up from $0.09 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.57 in Q3 2024 to a low of -$5.65 in Q2 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.35, with a median of $0.52 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 1478.05% in 2022, then surged 950.0% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.75 in 2021, then rose by 21.33% to $0.91 in 2022, then grew by 15.38% to $1.05 in 2023, then grew by 2.86% to $1.08 in 2024, then crashed by 50.0% to $0.54 in 2025.
  • Per Business Quant, the three most recent readings for CNMD's EPS (Weighted Average and Diluted) are $0.54 (Q4 2025), $0.09 (Q3 2025), and $0.69 (Q2 2025).